The settlement removes a key litigation overhang and provides long-term clarity on SUNOSI generic entry. Expect positive stock reaction. Monitor FTC/DOJ review, but such settlements are routine and likely to clear. This bolsters Axsome's revenue visibility and may support upward earnings revisions.
AXSM drugs
AXSM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 3 $233.49entry
- T+1 · 6mo ago −0.86%α −1.26% · $231.48
- T+5 · 5mo ago +5.50%α +9.32% · $246.34
- T+20 · 5mo ago +4.63%α +5.63% · $244.31
- T+60 · 3mo ago −11.66%α −14.16% · $206.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome settled all SUNOSI patent litigation, granting five generic companies entry rights no earlier than March 2040 (or September 2040 with pediatric exclusivity). This removes a major overhang and secures SUNOSI's exclusivity for over 14 years, significantly de-risking the product's long-term revenue stream.
Key Facts
- All outstanding SUNOSI patent litigation resolved via settlement with the only remaining first-to-file generic applicant.
- Five companies granted the right to sell generic SUNOSI beginning on or after September 1, 2040 (if pediatric exclusivity granted) or March 1, 2040 (if not), subject to FDA approval.
- No other SUNOSI patent litigation remains pending.
- Settlement will be submitted to FTC and DOJ for review.
Financial Impact
No specific financial terms disclosed, but extension of SUNOSI exclusivity to 2040 protects a key product generating significant revenue (SUNOSI is approved for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea). Generic entry delayed by over 14 years.
Risk Factors
- FTC or DOJ could challenge the settlement, though typical 'pay-for-delay' risks appear low given the broad licensing structure.
- If pediatric exclusivity is not granted, generic entry moves to March 2040 (still well in the future).
- SUNOSI revenue could be impacted by other competitive threats or label changes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254708 |
| Document: axsm-ex99_1.htm | 0001193125-26-254708 |
| Document: 0001193125-26-254708-index-headers.html | 0001193125-26-254708 |
| Document: 0001193125-26-254708-index.html | 0001193125-26-254708 |
| Document: 0001193125-26-254708.txt | 0001193125-26-254708 |
Track record
26 reports on AXSM
5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers